Clinical Trial Update: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan [Phase 2]

View source ↗

Summary

A Phase 2 efficacy trial of inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis in Japan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Alveolar Proteinosis

Drugs mentioned

• Leukine (sargramostim) (sargramostim)

Snippet

Sponsor: Niigata University Medical & Dental Hospital | Conditions: Pulmonary Alveolar Proteinosis, Autoimmune | Phase 2 | Status: COMPLETED